Bioage Labs Inc (BIOA) Stock Price, Quote & News

Company Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 510 806 1445

Website: bioagelabs.com

Address:

5885 Hollis Street, Suite 370, EmeryVille, United States

Rusty_Shackelford2024 Aug. 5 at 6:02 PM

$BIOA man, I’m holding here with an average of 9.40 wanting to sell this position several thousand dollars into the green. It’s coiled up like a spring though and I can see this hit in 15 or 16 before the end of the week.

0 · Reply

izjustlooking Aug. 5 at 4:12 PM

$BIOA get this back to 25

0 · Reply

BiodegradableBurger Aug. 5 at 2:27 PM

$BIOA Buying up started at 12pm yesterday so expecting the same…?

0 · Reply

teddy2 Aug. 4 at 6:09 PM

$BIOA I hope they talk the talk on Thursday’s earnings!!!!

0 · Reply

Gemini367 Aug. 4 at 5:46 PM

$BIOA done. Let's see if we can break $12 and send it higher. Best of luck.

0 · Reply

bluermefox Aug. 4 at 5:09 PM

$BIOA Twitching here

0 · Reply

Rusty_Shackelford2024 Aug. 4 at 11:46 AM

$BIOA easy win. 15 by close

0 · Reply

Roronao Aug. 4 at 9:18 AM

$CRWV $BIOA $SLSN B

0 · Reply

UnoffensiveName Aug. 4 at 1:32 AM

$BIOA Dear everyone who likes money: Simply put... $BIOA is getting hit on guilt-by-association. The other drug failed due to a target-specific toxicity. BIOA's issue was idiosyncratic transaminitis without a clear dose-response—a different mechanism entirely. This isn't a class effect, so the sympathy selloff isn't scientifically justified. I'm loading here

1 · Reply

UnoffensiveName Aug. 4 at 1:29 AM

$BIOA this cat's name should be BioRight instead of BioRich Why? Well... cuz hes right

0 · Reply

BioAge Labs reports Q2 EPS (58c), consensus (62c)

Aug 5, 2026, 4:50 PM EDT - 9 hours ago

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 5, 2026, 7:00 AM EDT - 19 hours ago

BioAge Labs Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 19 hours ago

BioAge Labs Earnings release: Q2 2026

2026-07-31T18:40:22.000Z - 5 days ago

BioAge Labs price target lowered to $25 from $36 at Roth Capital

NVO

2026-07-31T17:40:23.000Z - 5 days ago

BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

NVO

2026-07-31T17:30:33.000Z - 5 days ago

BioAge Labs price target lowered at Jefferies after Novo trial miss

NVO

2026-07-31T17:25:12.000Z - 5 days ago

BioAge Labs price target lowered to $50 from $60 at Oppenheimer

2026-06-16T12:08:19.000Z - 7 weeks ago

BioAge Labs doses first participant in QUELL-CV trial of BGE-102

Jun 16, 2026, 8:00 AM EDT - 7 weeks ago

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Jun 8, 2026, 2:40 PM EDT - 2 months ago

BioAge Labs Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 3:45 PM EDT - 2 months ago

BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026

2026-05-27T08:20:08.000Z - 2 months ago

BioAge Labs initiated with a Buy at Roth Capital

May 22, 2026, 9:00 AM EDT - 2 months ago

BioAge Labs to Present at Upcoming Investor Conferences

2026-05-13T09:55:09.000Z - 3 months ago

BioAge Labs initiated with a Buy at BTIG

May 8, 2026, 12:30 PM EDT - 3 months ago

BioAge Labs Transcript: R&D Day 2026

May 8, 2026, 12:30 PM EDT - 3 months ago

BioAge Labs Slides: FY 2026

2026-05-08T15:21:29.000Z - 3 months ago

BioAge Labs reports Q1 EPS (52c), consensus (63c)

May 8, 2026, 9:00 AM EDT - 3 months ago

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026, 7:00 AM EDT - 3 months ago

BioAge Labs Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

BioAge Labs Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

2026-04-21T12:30:33.000Z - 3 months ago

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

Apr 21, 2026, 8:00 AM EDT - 3 months ago

BioAge Labs Transcript: Study result

Apr 21, 2026, 8:00 AM EDT - 3 months ago

BioAge Labs Press release: Study result

Apr 21, 2026, 8:00 AM EDT - 3 months ago

BioAge Labs Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

BioAge Labs Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 3 months ago

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

Apr 20, 2026, 7:00 AM EDT - 3 months ago

BioAge Labs Slides: Corporate presentation

Apr 16, 2026, 3:00 PM EDT - 3 months ago

BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 4:30 PM EDT - 4 months ago

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

2026-03-27T10:27:07.000Z - 4 months ago

BioAge Labs initiated with a Buy at Needham

2026-03-24T20:25:15.000Z - 4 months ago

BioAge Labs files automatic mixed securities shelf

Mar 24, 2026, 9:00 AM EDT - 4 months ago

BioAge Labs Annual report: Q4 2025

Mar 24, 2026, 9:00 AM EDT - 4 months ago

BioAge Labs Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 4 months ago

BioAge Labs Slides: Corporate presentation

2026-03-10T10:41:09.000Z - 5 months ago

BioAge Labs price target raised to $52 from $15 at Citi

Feb 26, 2026, 10:40 AM EST - 5 months ago

BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-24T21:48:29.000Z - 5 months ago

BioAge Labs initiated with an Outperform at Oppenheimer

VTYX

2026-02-18T11:10:46.000Z - 6 months ago

BioAge Labs upgraded to Buy from Hold at Jefferies

2026-02-04T13:36:59.000Z - 6 months ago

BioAge Labs price target raised to $23 from $12 at Morgan Stanley

2026-01-27T10:15:29.000Z - 6 months ago

BioAge Labs initiated with an Overweight at Piper Sandler

Jan 21, 2026, 10:30 PM EST - 7 months ago

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

Jan 20, 2026, 4:01 PM EST - 7 months ago

BioAge Announces Proposed Public Offering

Jan 20, 2026, 9:00 AM EST - 7 months ago

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

Jan 20, 2026, 7:00 AM EST - 7 months ago

BioAge Labs Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 7 months ago

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

Dec 4, 2025, 1:30 PM EST - 8 months ago

BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 9:00 AM EST - 8 months ago

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Nov 25, 2025, 4:30 PM EST - 9 months ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:30 AM EST - 9 months ago

BioAge Labs Transcript: Jefferies London Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 9 months ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:00 PM EST - 9 months ago

BioAge Labs Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

BioAge Labs Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

BioAge Labs Registration statement: Registration Filing

Nov 5, 2025, 7:00 AM EST - 9 months ago

BioAge Labs Registration statement: Registration Filing

Oct 2, 2025, 8:00 AM EDT - 10 months ago

BioAge Labs Registration statement: Registration Filing

Oct 2, 2025, 8:00 AM EDT - 10 months ago

BioAge Labs Registration statement: Registration Filing

Sep 15, 2025, 9:30 AM EDT - 11 months ago

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Sep 10, 2025, 10:00 AM EDT - 11 months ago

BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 3:15 PM EDT - 1 year ago

BioAge Labs Transcript: Citi's Biopharma Back to School Conference

Aug 15, 2025, 9:00 AM EDT - 1 year ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Aug 6, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 4:00 PM EDT - 1 year ago

BioAge Labs Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

BioAge Labs Earnings release: Q2 2025

Jun 21, 2025, 6:00 PM EDT - 1 year ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Jun 17, 2025, 9:00 AM EDT - 1 year ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

Jun 9, 2025, 3:20 PM EDT - 1 year ago

BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 6:00 AM EDT - 1 year ago

BioAge Labs Slides: Investor Presentation

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 12:00 AM EDT - 1 year ago

BioAge Labs Quarterly report: Q1 2025

May 6, 2025, 12:00 AM EDT - 1 year ago

BioAge Labs Earnings release: Q1 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

BioAge Labs Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

BioAge Labs Proxy statement: Proxy Filing

Mar 20, 2025, 5:00 PM EDT - 1 year ago

BioAge Labs Annual report: Q4 2024

Mar 20, 2025, 5:00 PM EDT - 1 year ago

BioAge Labs Earnings release: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Mar 10, 2025, 9:30 PM EDT - 1 year ago

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

Mar 10, 2025, 6:33 PM EDT - 1 year ago

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 5, 2025, 3:45 PM EST - 1 year ago

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 2, 2025, 7:23 AM EST - 1 year ago

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

Feb 28, 2025, 3:30 PM EST - 1 year ago

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Rusty_Shackelford2024 Aug. 5 at 6:02 PM

0 · Reply

izjustlooking Aug. 5 at 4:12 PM

$BIOA get this back to 25

0 · Reply

BiodegradableBurger Aug. 5 at 2:27 PM

$BIOA Buying up started at 12pm yesterday so expecting the same…?

0 · Reply

teddy2 Aug. 4 at 6:09 PM

$BIOA I hope they talk the talk on Thursday’s earnings!!!!

0 · Reply

Gemini367 Aug. 4 at 5:46 PM

$BIOA done. Let's see if we can break $12 and send it higher. Best of luck.

0 · Reply

bluermefox Aug. 4 at 5:09 PM

$BIOA Twitching here

0 · Reply

Rusty_Shackelford2024 Aug. 4 at 11:46 AM

$BIOA easy win. 15 by close

0 · Reply

Roronao Aug. 4 at 9:18 AM

$CRWV $BIOA $SLSN B

0 · Reply

UnoffensiveName Aug. 4 at 1:32 AM

1 · Reply

UnoffensiveName Aug. 4 at 1:29 AM

$BIOA this cat's name should be BioRight instead of BioRich Why? Well... cuz hes right

0 · Reply

topstockalerts Aug. 3 at 8:12 PM

$BIOA just watching how it reacts here… key spot

1 · Reply

teddy2 Aug. 3 at 4:56 PM

$BIOA keep it coming!!!

0 · Reply

kp8claw Aug. 3 at 4:53 PM

0 · Reply

Rusty_Shackelford2024 Aug. 3 at 4:37 PM

$BIOA 15 on deck

0 · Reply

BioRich Aug. 3 at 3:21 PM

$BIOA Nice bounceback. Oversold/overreaction = Great Buying opportunity. Hope folks jumped on the drop Friday. Follow/Subscribe for more suggestions and perspective Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

Gemini367 Aug. 3 at 3:08 PM

$BIOA $11 on deck.

0 · Reply

teddy2 Aug. 3 at 2:07 PM

$BIOA looking forward to seeing this rise up!!!

0 · Reply

izjustlooking Aug. 3 at 2:03 PM

$BIOA looking good for rebound

0 · Reply

Rusty_Shackelford2024 Aug. 3 at 11:59 AM

$BIOA @DougieFreshPicks check this one out. Lost 60% Friday because $NVO failed in phase 3 of a similar drug. BIOA has a totally different molecule.

1 · Reply

Rusty_Shackelford2024 Aug. 3 at 11:57 AM

$BIOA as I said on Friday don’t be surprised if 15 become the new support this week. One of the better “no news” rebound plays I can remember since that no new Harley Davidson dump a few years back.

0 · Reply

GordonGordon Aug. 3 at 11:45 AM

$BIOA On Friday, Needham maintained Buy with a $35 price target. Jeffries maintained their Buy but with a $21 price target.

0 · Reply

GordonGordon Aug. 3 at 11:43 AM

$BIOA BTIG reiterated a Buy and maintained $40 price target.

0 · Reply

Market Cap	479.20M
Revenue (ttm)	9.00M
Net Income (ttm)	-80.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-895.67%
Debt to Equity Ratio	0.00

Volume	1,128,000
Avg Vol	907,944
Day's Range	N/A - N/A
Shares Out	44.45M
Stochastic %K	14%
Beta	0.94
Analysts	Strong Sell
Price Target	$39.88